Weight Loss Injections and Kidney Stones: What the Evidence Says

Is there a known link between GLP-1 medicines and kidney stones?

This is a question our prescribers hear most weeks, and the honest answer is: no direct causal link has been established. Neither Mounjaro (tirzepatide) nor Wegovy (semaglutide) are listed as medicines that cause kidney stones in their approved UK prescribing information, and the major clinical trials (including SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide) did not flag kidney stone formation as a notable adverse event. The NHS medicines page for tirzepatide and the equivalent page for semaglutide describe side effects in detail; kidney stones do not appear there.

That said, research into GLP-1 receptor agonists and kidney health is ongoing, and the absence of a confirmed link is not the same as a confirmed absence of risk. Some smaller observational studies have explored the relationship in both directions, and results are mixed enough that no firm conclusion has been drawn. If you are prone to oxalate stones specifically, rapid dietary changes during treatment (eating less overall, fewer certain foods) can occasionally shift urinary chemistry. Discussing this with your GP or a urologist before starting is sensible, not overcautious. You can also read more about the broader question of whether weight loss injections can cause kidney stones in our dedicated page on that topic.

Could losing weight through these medicines actually help with stone risk?

Possibly, yes, and this is an angle that often gets overlooked. Obesity is a well-documented risk factor for kidney stones, particularly uric acid and calcium oxalate stones. Insulin resistance, which frequently accompanies excess weight, lowers urine pH and raises uric acid excretion, creating conditions that favour stone formation. Reducing body weight, improving insulin sensitivity, and shifting metabolic markers over time may all work in the other direction. The NHS obesity treatment guidance recognises that sustained weight loss carries wide-ranging health benefits, and kidney health is part of that picture.

Tirzepatide in particular showed significant improvements in metabolic markers across the SURMOUNT programme. For people whose kidney stones are tied to metabolic factors (raised uric acid, high insulin, excess weight) a medicine that addresses those upstream drivers might reduce recurrence risk over time, though no trial has yet tested this directly. It is not a guaranteed benefit, and it does not substitute for the dietary and hydration advice a urologist or dietitian would give you. If you have also been told you have gallstones, our page on weight loss injections and gallstones covers what that means for your treatment choices.

For a wider look at how these treatments interact with kidney function more broadly, our page on weight loss injections and kidney disease covers that ground in detail.

What about dehydration, does that increase the risk?

This is the most practically important consideration for anyone who has had kidney stones. GLP-1 medicines commonly cause gastrointestinal side effects (nausea, loose stools, vomiting) especially in the early weeks of treatment or after a dose increase. If those symptoms lead to poor fluid intake or fluid loss, urine becomes more concentrated. Concentrated urine is exactly the environment in which stone crystals form more readily. The NHS semaglutide medicines page lists these GI effects clearly, and the same profile applies to tirzepatide.

The practical message is straightforward: staying well hydrated during treatment is always important, and it matters even more if you have a stone history. Aim for pale straw-coloured urine as a rough guide, and if vomiting or diarrhoea is severe enough that you cannot keep fluids down, seek medical advice promptly rather than waiting it out. The MHRA advises that significant dehydration during GLP-1 treatment can also affect kidney function more broadly, a point that applies with extra force to people who already have reduced kidney reserve. You can read about that specific concern on our page covering whether weight loss injections can cause kidney problems.

Who should talk to a specialist before starting, and what should they ask?

Anyone with a history of recurrent kidney stones, a known metabolic stone-forming condition (such as hyperoxaluria or cystinuria), or concurrent kidney disease should discuss treatment with their GP or nephrologist before beginning weight loss injections. That conversation does not necessarily mean you cannot use these medicines, it means starting with a clear picture. Questions worth raising: what type of stones you form, whether your stone risk is linked to metabolic factors that weight loss might improve, whether your kidney function is fully normal, and whether any hydration or dietary strategy should run alongside treatment.

At nume, a prescriber reviews your health history in detail before any prescription is issued. There are no shortcuts to that step. If your history includes complex kidney conditions, your prescriber may want a letter from your GP or specialist confirming it is safe to proceed, that is a feature of careful prescribing, not a barrier for its own sake. If you would like to understand the clinical criteria in more detail, our page on taking weight loss injections with kidney disease covers the eligibility picture, and you can explore your options further on our treatment consultation page. People who have never injected before may also find the practical side covered on our guide to self-injection reassuring.